Med. Pro Praxi 2007; 2: 70-72

Kardiovaskulární onemocnění a hypolipidemická léčba

MUDr. Michal Vrablík Ph.D
III. interní klinika VFN a 1. LF UK, Praha

Hypolipidemika jsou standardní součástí léčby nemocných se zvýšeným kardiovaskulárním rizikem. Riziko stanovujeme vyhonocením co největšího počtu rizikových faktorů s pomocí algoritmů (např. SCORE). Odhad rizika lze zpřesnit při využití moderních metod neinvazivní detekce aterosklerózy. Rozhodnutí o hypolipidemické farmakologické léčbě závisí na míře rizika a koncentraci sérových lipidů. V první řadě se intervence zaměřuje na dosažení cílových hladin LDL-c, dalšími cíli jsou normalizace hladiny triglyceridů a zvýšení koncentrací HDL-c. Řada nemocných bude profitovat z péče specializovaných pracovišť, která povedou léčbu vysokými dávkami či kombinací hypolipidemik, budou zajišťovat péči o nemocné s geneticky podmíněnými riziky.

Keywords: hypolipidemická léčba, statiny, ezetimib, fibráty, kardiovaskulární riziko, zobrazovací techniky, specializovaná péče

Published: April 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M. Kardiovaskulární onemocnění a hypolipidemická léčba. Med. praxi. 2007;4(2):70-72.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialist (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: Prospective meta-anylysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-1278. Go to original source... Go to PubMed...
    2. Conroy R, Pyorala K, Fitzgerald A et al. Prediction of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003. Go to original source... Go to PubMed...
    3. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952. imaging techniques. Go to original source... Go to PubMed...
    4. Grundy SM, Cleenam JI, Bairey CN et al. Implication of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-239. Go to original source... Go to PubMed...
    5. Bultas J. Kombinační léčba dyslipidémií. Interní Med 2006, 7-8:314-322.
    6. Farnier M, Freeman MW, Macdonell G et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26: 897-905. Go to original source... Go to PubMed...
    7. Davidson MH, Ballantyne CM, Kerzner B et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004; 58: 746-755. Go to original source... Go to PubMed...
    8. Vrablík M, Štulc T, Králíková E et al. Statiny, fibráty a jejich kombinace v léčbě hyperlipoproteinémií. Medicína po promoci 2004, 5 (4): 53-59.
    9. Buse JB, Ginsberg HN, Bakris GL et al. American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007 Jan 2;115(1):114-126. Epub 2006 Dec 27. Go to original source... Go to PubMed...
    10. Cífková R a členové pracovní skupiny. Prevence kardiovaskulárních onemocnění v dospělém věku. Cor Vasa 2005, 47(9Suppl): 3-14.
    11. DeBacker G, Ambrosioni E, Borch-Johnsen K et al.; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-1610. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.